30. Juni 2015

DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products

New Half-Life Extension Platform Technology Will Support the Development and Commercialization of
Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology

Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company
with a team of experienced industry professionals with a long and successful track record of
developing and manufacturing biopharmaceutical products, and XL-protein GmbH (“XLp”), a leader in
protein engineering and modification technologies, today announced a collaboration for the
development and commercialization of novel, long-acting biopharmaceutical products. Under this
strategic collaboration,
XLp will contribute its half-life extension platform technology (PASylation®) and certain molecules
have completed in vivo efficacy proof-of-concept and preclinical studies, and DNX will add its
pipeline of candidate molecules for development and commercialization to address a range of unmet
needs in Immunology, Metabolism and Ophthalmology. Financial terms have not been disclosed.

Half-life extension is a critical aspect of developing a successful protein pharmaceutical, as not
all efficacious payloads have natural half-lives that are amenable to reasonable dosing intervals
or regimens. The novel PASylation platform is designed to offer improved half-life,
pharmacokinetics, pharmacodynamics, bioavailability, solubility and overall enhanced patient
compliance and safety. PASylation is a highly tunable technology and offers a paradigm shift in
patient care and better compliance in multiple therapeutic areas to improve the quality of life for
millions of patients.

“We are pleased to be partnering with XL-protein on the development of new molecules specifically
designed to improving the lives of patients, while simultaneously helping to alleviate the clinical
burden,” said Dr. Rajiv Datar, Chief Executive of DNX. “By combining DNX’s 250+ person-years of
experience of biologics process development, clinical development and GMP manufacturing expertise
with XLp’s revolutionary PASylation platform, we hope to ‘Make Good Drugs Great,’ and to delivering
more gain and less pain to patients.”

“Working with DNX to create a range of novel long-acting biopharmaceuticals that will provide
benefits to patients and to the healthcare services by reducing clinical burden is exciting and
satisfying,” said Claus Schalper, Managing Director of XL-protein. “Our team shares a common
passion with DNX to
‘Making Good Drugs Even Greater’ by contributing our half-life extension / drug delivery technology
to support successful product development and commercialization.”

About DNX
DNX is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of
patients with life-long diseases. Headquartered in Irvine, CA, USA, DNX is pursuing the
development of new therapeutic proteins utilizing 21st century, half-life extension-based drug
delivery technologies. www.dnxbio.com

About XL-protein
XL-protein is a German biotech company commercializing the ground-breaking PASylation technology,
which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action.
With its strong proprietary technology position XL-protein focuses at the preclinical as well as
clinical development of PASylated proteins in various disease areas. The company is located at
Germany, in the neighborhoods of Munich International Airport and the Technical University of

Contact: Uli Binder, CTO, XL-protein GmbH, +49 8161 53730 90, bd@xl-protein.com

Immer informiert bleiben: